Piper Sandler Sticks to Their Buy Rating for Conmed (CNMD)
Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)
JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating
Conmed Analyst Ratings
Conmed Performance Review: Hold Rating With Cautious Growth and Margin Outlook
Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Roche Holding AG (OtherRHHVF) and Sanofi (OtherSNYNF)
Hold Rating on Conmed Amid Competitive Pressures and Growth Uncertainties
Analysts Are Bullish on These Healthcare Stocks: Conmed (CNMD), Illumina (ILMN)
Analysts Are Bullish on These Healthcare Stocks: Conmed (CNMD), Resmed (RMD)
Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating
Hold Rating on Conmed: Balancing Double-Digit Revenue Growth and Market Challenges
Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Edwards Lifesciences (EW) and Prothena (PRTA)
Hold Rating on Conmed Amid Strong Q3 Performance and Anticipated Supply Constraints
Analysts' Opinions Are Mixed on These Healthcare Stocks: Conmed (CNMD), Keros Therapeutics (KROS) and Stericycle (SRCL)
Needham Maintains Buy on Conmed, Lowers Price Target to $119
Conmed Analyst Ratings
Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating
Keybanc Maintains Overweight on Conmed, Raises Price Target to $141
Conmed Analyst Ratings
Analyst Ratings for Conmed
No Data